Key Insights

Highlights

Treatment Research

3 treatments under study, led by Imiglucerase Gz437843

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03485677Phase 3Completed

Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

Showing all 1 trials

Research Network

Common Treatments

  • Imiglucerase Gz4378431
  • Eliglustat Gz3856601
  • Eliglustat Tartrate1

Active Sponsors

  • Sanofi1
  • Genzyme Corp.1

Related Conditions

  • Gauchers Disease Type I1
  • Gauchers Disease Type Iii1

Activity Timeline